MorphoSys to present MANIFEST and RE-MIND2 data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting

MEDIA RELEASE

MorphoSys to present MANIFEST and RE-MIND2 data from expanded

hematology-oncology portfolio at the 2021 American Society of

Hematology (ASH) Annual Meeting

• Updates from MANIFEST phase 2 trial in patients with myelofibrosis, including clinical updates on JAK naïve patients treated with pelabresib in combination with ruxolitinib, including translational data
• • • MANIFEST update on pelabresib monotherapy in patients with myelofibrosis
  • Expanded Real-WorldRE-MIND2 dataset comparing outcomes for tafasitamab plus

lenalidomide versus pola-BR, R2, and CAR T in relapsed/refractory diffuse large B-Cell

lymphoma

PLANEGG/MUNICH, Germany - November 4, 2021 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that new data on approved and clinical-stage therapeutics will be presented during the American Society of Hematology (ASH) Annual Meeting from December 11-14 in Atlanta, Georgia United States. Ten abstracts were accepted, including two oral presentations, from the comprehensive MorphoSys portfolio, including abstracts for the BET inhibitor pelabresib, which MorphoSys added to its pipeline through the acquisition of Constellation Pharmaceuticals.

"MorphoSys continues to contribute significantly to scientific advances in hematology-oncology with our cancer immunotherapy and our expanded portfolio including the development of epigenetic modifiers," said Malte Peters, MD, MorphoSys Chief Research and Development Officer. "The important data published in our ASH presentations show our commitment to finding cures that redefine how cancer is treated."

The MANIFEST and RE-MIND2 presentations at ASH 2021 are the culmination of a transformational year for MorphoSys. Through groundbreaking proprietary research in immunotherapy and the addition of Constellation Pharmaceuticals' high-potential product candidates, MorphoSys has bolstered its position as an emerging leader in hematology- oncology.

Highlights of presentations from the MorphoSys hematology-oncology portfolio include:

• An update of clinical and translational data from the ongoing MANIFEST trial for JAK naïve patients treated with pelabresib (CPI-0610) in combination with ruxolitinib (study arm 3), representing the analysis for the primary endpoint SVR35
• An update of clinical and translational data from the ongoing MANIFEST trial for pelabresib (CPI-0610) monotherapy in patients with myelofibrosis
• Expanded Real-WorldRE-MIND2 dataset comparing tafasitamab and lenalidomide (Tafa+Len) outcomes to those observed in matched cohorts of 1) polatuzumab vedotin plus bendamustine and rituximab (pola-BR), 2) rituximab plus lenalidomide (R2); and 3) CAR-T therapies

Follow MorphoSys on Twitter via @MorphoSys and visit the MorphoSys ASH virtual booth at www.MorphoSysEvents.com

PELABRESIB ASH 2021 ACCEPTED ABSTRACTS

Study	Abstract Title	Authors	Status / Publication # /
			Session
MANIFEST	Pelabresib (CPI-0610)	Marina Kremyanskaya,	Oral Presentation
	Monotherapy in Patients with	John Mascarenhas,	#141
	Myelofibrosis - Update	Francesca Palandri, Alessandro	Session Name: 634.
	of Clinical and Translational	M. Vannucchi, Srdan Verstovsek,	Myeloproliferative Syndromes:
	Data from the Ongoing	Claire Harrison, Prithviraj Bose,	Clinical and
	MANIFEST Trial	Gary J. Schiller, Raajit K. Rampal,	Epidemiological: Non-JAK
		Mark W. Drummond, Vikas Gupta,	inhibitor Therapies for
		Andrea Patriarca, Nikki Granacher,	Myelofibrosis
		Joseph Scandura, Witold Prejzner,	Session Date: Saturday,
		Lino Teichmann, Natalia Curto-	December 11, 2021
		García, Ronald Hoffman, Gozde	Session Time: 12:00 PM - 1:30
		Colak, Zheng Ren,	PM
		Suresh Bobba, Jike Cui, Sergey	Presentation Time: 12:30 PM
		Efuni, Moshe Talpaz	Room: Georgia World Congress
			Center, A411-A412
Pelabresib	PK and PD Assessment of	Kristie A. Blum, Jeffrey Supko,	POSTER
Ph1	BET Inhibitor Pelabresib (CPI-	Michael Maris, Ian Flinn, Andre	#1202
	0610) in Patients With	Goy, Anas Younes, Suresh Bobba,	Session Name: 605. Molecular
	Relapsed or Refractory	Adrian Senderowicz, Sergey	Pharmacology and Drug
	Lymphoma: Findings from a	Efuni, Ronda Rippley, Jeremy S.	Resistance:
	Phase 1 Study	Abramson	Lymphoid Neoplasms: Poster I
			Date: Saturday, December 11,
			2021
			Presentation Time: 5:30 PM -
			7:30 PM
			Location: Georgia World
			Congress Center, Hall B5
MANIFEST	Disease-Modifying Potential of	Srdan Verstovsek, Mohamed E.	Accepted as poster
	BET Inhibitor Pelabresib (CPI-	Salama, John Mascarenhas,	#2568
	0610) as Demonstrated by	Moshe Talpaz, Ruben Mesa,	Session Name: 634.
	Improvements in Bone Marrow Alessandro M. Vannucchi, Raajit K.	Myeloproliferative Syndromes:
	Function and Clinical Activity in Rampal, Stephen Oh,	Clinical and
	Patients With Myelofibrosis -	Horatiu Olteanu, April Chiu, Dong	Epidemiological: Poster II
	Preliminary Data	Chen, Curtis A Hanson,	Date: Sunday, December 12,
		Natalia Curto-García, Pietro	2021
		Taverna, Jike Cui,	Presentation Time: 6:00 PM -
		Oksana Zavidij, Zehua Chen,	8:00 PM
		Gozde Colak, Sergey Efuni, Patricia Location: Georgia World
		Keller, Patrick Trojer, Claire	Congress Center, Hall B5
		Harrison

TAFASITAMAB ASH 2021 ACCEPTED ABSTRACTS

Study	Abstract Title	Authors	Status / Publication # /
			Session
RE-MIND2	Tafasitamab plus	Grzegorz S. Nowakowski, Dok	Accepted as oral presentation
	Lenalidomide versus pola-BR,	Hyun Yoon, Patrizia Mondello,	#183
	R2, and CAR T: Comparing	Erel Joffe, Anthea Peters,	Session Name: 905. Outcomes
	Outcomes from RE-MIND2, an	Isabelle Fleury, Richard Greil,	Research-Lymphoid
	Observational, Retrospective	Matthew Ku, Reinhard Marks,	Malignancies: Lymphoma/CLL
	Cohort Study in	Kibum Kim, Pier Luigi Zinzani,	Real-World Data
	Relapsed/Refractory Diffuse	Judith Trotman, Lorenzo	Session Date: Saturday,
	Large B-Cell Lymphoma	Sabatelli, Dan Huang, Eva E.	December 11, 2021
		Waltl, Mark Winderlich, Sumeet	Session Time: 12:00 PM - 1:30
		Ambarkhane, Nuwan C.	PM
		Kurukulasuriya, Raul Cordoba,	Presentation Time: 12:30 PM
		Georg Hess, Gilles Salles	Room: Georgia World Congress
			Center, Sidney Marcus
			Auditorium
Shared	Preferences and Perceptions	Mallory Yung, Frederick Schnell,	Accepted as poster
Decision	Regarding Treatment	Mirko Vukcevic, Nuwan C.	(collaboration with Avalere)
Making in	Decision-Making For	Kurukulasuriya	#1928
R/R DLBCL	Relapsed or Refractory		Session Name: 902. Health
	Diffuse Large B-Cell		Services Research-Lymphoid
	Lymphoma (R/R DLBCL)		Malignancies: Poster I
			Date: Saturday, December 11,
			2021
			Presentation Time: 5:30 PM -
			7:30 PM
			Location: Georgia World
			Congress Center, Hall B5
inMIND	inMIND: A Phase 3 Study of	Sehn L, Luminari S, Salar A,	Accepted as poster
(Incyte)	Tafasitamab Plus	Wahlin B, Gopal A, Bonnet C,	Session Name: 623. Mantle
	Lenalidomide and Rituximab	Paneesha S, Trneny M, Manzke	Cell, Follicular, and Other
	Versus Placebo Plus	O, Seguy F, Li D, Hubel K,	Indolent B Cell Lymphomas:
	Lenalidomide and Rituximab	Scholz C	Clinical and Epidemiological:
	for Relapsed/Refractory		Poster II
	Follicular or Marginal Zone		Date: Sunday, December 12,
	Lymphoma		2021
			Presentation Time: 6:00 PM -
			8:00 PM
Tafasitamab	The SUMOylation Inhibitor	Maria Patra-Kneuer, Akito	Accepted as poster
+ TAK981	TAK-981 in Combination with	Nakamura, Keli Song, Stephen	#2268
preclinical	the CD19-Targeting Antibody	Grossman, Andrea Polzer,	Session Name: 605. Molecular
	Tafasitamab Shows Enhanced	Carmen Ginzel, Stefan Steidl,	Pharmacology and Drug
	Anti-Tumor Activity in	Allison J Berger, Igor	Resistance: Lymphoid
	Preclinical B-Cell Lymphoma	Proscurshim, Christina	Neoplasms: Poster II
	Models	Heitmüller	Date: Sunday, December 12,
			2021
			Presentation Time: 6:00 PM -
			8:00 PM
			Location: Georgia World
			Congress Center, Hall B5

	Tafasitamab	The Impact of Prior Treatment	Reona Sakemura, Claudia	Accepted as poster
	+ CAR-T	with a CD19 Targeting	Manriquez Roman, Paulina	(collaboration with Mayo Clinic)
	preclinical	Monoclonal Antibody on	Horvei, Ekene Ogbodo, Erin E.	#2412
		Subsequent Treatment with	Tapper,Elizabeth L. Siegler,	Session Name: 622.
		CD19 Targeting CART Cell	Carli M. Stewart, Kendall J.	Lymphomas: Translational-
		Therapy in Preclinical Models	Schick, Ismail Can, Mohamad	Non-Genetic: Poster II
			M. Adada, Evandro D. Bezerra,	Date: Sunday, December 12,
			Lionel Aurelien A. Kankeu	2021
			Fonkoua, Mehrdad Hefazi,	Presentation Time: 6:00 PM -
			Michael W. Ruff, Christian	8:00 PM
			Augsberger, Jürgen Schanzer,	Location: Georgia World
			Maria Patra-Kneuer, Christina	Congress Center, Hall B5
			Heitmüller, Stefan Steidl, Jan
			Endell, Wei Ding, Sameer A.
			Parikh, Neil E. Kay, Greg
			Nowakowski, Michelle J. Cox,
			Saad S. Kenderian
	First-MIND	First-MIND: Primary Analysis	David Belada, Katerina	Accepted as poster
		from a Phase Ib, Open-Label,	Kopeckova, Juan Miguel Bergua	#3556
		Randomized Study to Assess	Burgues, Don Stevens, Marc	Session Name: 626. Aggressive
		Safety of Tafasitamab or	André, Ernesto Perez Persona,	Lymphomas: Prospective
		Tafasitamab + Lenalidomide in	Petra Pichler, Philipp Staber,	Therapeutic Trials: Poster III
		Addition to R-CHOP in	Marek Trneny, Bettina	Date: Monday, December 13,
		Patients with Newly	Brackertz, Neha Shah, Andrea	2021
		Diagnosed Diffuse Large B-	Sporchia, John M. Burke,	Presentation Time: 6:00 PM -
		cell Lymphoma	Grzegorz S. Nowakowski	8:00 PM
				Location: Georgia World
				Congress Center, Hall B5
	First-MIND	Disease kinetics measured by	Mouhamad Khouja, Anke	Accepted as poster with short
	MRD	ctDNA correlates with	Schillhabel, Michaela Kotrova,	presentation (collaboration with
	Analysis	treatment response after	Nikos Darzentas, Christian	Univ. of Kiel) / #3498
		tafasitamab in combination	Kuffer, Derek Blair, Monika	Session Name: 621.
		with R-CHOP with or without	Brüggemann, Christiane Pott	Lymphomas: Translational-
		lenalidomide in first line		Molecular and Genetic: Poster
		treatment of DLBCL		III
				Date: Monday, December 13,
				2021
				Presentation Time: 6:00 PM -
				8:00 PM
				Location: Georgia World
				Congress Center, Hall B5

About Tafasitamab

Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependentcell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

Monjuvi®(tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued

approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. Monjuvi® is being co-commercialized by Incyte and MorphoSys in the United States. Incyte has exclusive commercialization rights outside the United States.

In Europe, Minjuvi® (tafasitamab) received conditional approval, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials.

Minjuvi® and Monjuvi® are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi® in the U.S., and marketed by Incyte under the brand name Minjuvi® in the EU.

XmAb® is a registered trademark of Xencor, Inc.

About MANIFEST

MANIFEST is an open-label Phase 2 clinical trial of pelabresib (CPI-0610) in patients with myelofibrosis (MF), a rare cancer of the bone marrow that disrupts the body's normal production of blood cells. Constellation is evaluating pelabresib in combination with ruxolitinib in JAK-inhibitor-naïve MF patients (Arm 3), with a primary endpoint of the proportion of patients with a ≥35% spleen volume reduction from baseline (SVR35) after 24 weeks of

treatment. Constellation Pharmaceuticals is also evaluating pelabresib either as a monotherapy in patients who are resistant to, intolerant of, or ineligible for ruxolitinib and no longer on the drug (Arm 1), or as add-on therapy in combination with ruxolitinib in patients with a sub-optimal response to ruxolitinib or MF progression (Arm 2). Patients in Arms 1 and 2 are being stratified based on transfusion dependent (TD) status. The primary endpoint for the patients in cohorts 1A and 2A, who were TD at baseline, is conversion to transfusion independence for 12 consecutive weeks. The primary endpoint for patients in cohorts 1B and 2B, who were not TD at baseline, is the proportion of patients with a ≥35% spleen volume reduction from baseline after 24 weeks of treatment.

About MorphoSys

MorphoSys (FSE & NASDAQ: MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya® (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi® (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.comor www.morphosys-us.com.

Monjuvi® is a registered trademark of MorphoSys AG.

Tremfya® is a registered trademark of Janssen Biotech, Inc.

MorphoSys Forward-Looking Statements

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may